Choreatic Symptoms During and After Treatment with Paliperidone and Escitalopram

Paliperidone, the first orally applicable atypical neuroleptic marketed as an extended-release preparation, is generally well tolerated [1] [5]. Over the last weeks, we have observed several young patients with schizophrenia, who showed significant akathisia during paliperidone treatment. Here we report the case of a depressed and psychotic patient who developed a dramatic choreatic syndrome during treatment with escitalopram and paliperidone.

References

• 1 Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.  Schizophrenia Res. 2007;  93 117-130
• 2 Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.  Psychopharmacology. 2007;  194 63-72
• 3 Förstl H, Pohlmann-Eden B. Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antidepressant-induced myoclonus.  Neurology. 1990;  40 924-926
• 4 Karlsson P, Hargarter L, Dencker E. et al . Pharmacokinetics and dopamine D2 and serotonin 5-HT2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies.  Pharmacopsychiatry. 2007;  40 , 227
• 5 Meltzer H, Hargarter L, Kramer M. et al . Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies.  Pharmacopsychiatry. 2007;  40 , 222
• 6 Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.  J Clin Psychopharmacol. 2005;  25 527-532

Correspondence